Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cilastatin Sodium

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cilastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Cilastatin Sodium reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cilastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cilastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

    NCT04801043 · start 2021-03-02

    Registered record
    Registry ID
    NCT04801043
    Conditions
    Bacterial Infections
    Interventions
    XNW4107; Imipenem/Cilastatin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-02
    Completion
    2022-01-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionXNW4107; Imipenem/Cilastatin; placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

    NCT04787562 · start 2021-02-25

    Registered record
    Registry ID
    NCT04787562
    Conditions
    Bacterial Infections
    Interventions
    XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-25
    Completion
    2022-02-28
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionXNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin; XNW4107, Imipenem/Cilastatin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam PK in ECMO

    NCT04493151 · start 2021-01-01

    Registered record
    Registry ID
    NCT04493151
    Conditions
    Sepsis
    Interventions
    Imipenem, Cilastatin and Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2023-06-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionImipenem, Cilastatin and Relebactam
    PhasePhase 1
    Registry statusCompleted

  • In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

    NCT04196608 · start 2019-11-01

    Registered record
    Registry ID
    NCT04196608
    Conditions
    Ceftolozane/Tazobactam; Imipenem/Relebactam; Hematology and Oncology
    Interventions
    Ceftolozane/tazobactam; imipenem- relebactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2020-09-30
    Enrolment
    1,005

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCeftolozane/Tazobactam; Imipenem/Relebactam; Hematology and Oncology
    InterventionCeftolozane/tazobactam; imipenem- relebactam
    PhaseNot recorded
    Registry statusUnknown

  • Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

    NCT03969901 · start 2019-10-08

    Registered record
    Registry ID
    NCT03969901
    Conditions
    Suspected or Documented Gram-negative Bacterial Infection
    Interventions
    IMI/REL; Active Control; Oral Switch
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-10-08
    Completion
    2024-05-07
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuspected or Documented Gram-negative Bacterial Infection
    InterventionIMI/REL; Active Control; Oral Switch
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

    NCT03894046 · start 2019-09-05

    Registered record
    Registry ID
    NCT03894046
    Conditions
    Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Colistin Resistant ABC
    Interventions
    Sulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-05
    Completion
    2021-07-26
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia +1 more
    InterventionSulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    PhasePhase 3
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

    NCT03583333 · start 2018-09-18

    Registered record
    Registry ID
    NCT03583333
    Conditions
    Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia
    Interventions
    IMI/REL FDC; PIP/TAZ FDC; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-18
    Completion
    2022-07-12
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia
    InterventionIMI/REL FDC; PIP/TAZ FDC; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

    NCT03858387 · start 2018-09-01

    Registered record
    Registry ID
    NCT03858387
    Conditions
    Critical Illness; Bacterial Infections
    Interventions
    Meropenem; Imipenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-01
    Completion
    2021-12-31
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Bacterial Infections
    InterventionMeropenem; Imipenem
    PhaseNot recorded
    Registry statusUnknown

  • Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.

    NCT03595189 · start 2018-06-19

    Registered record
    Registry ID
    NCT03595189
    Conditions
    Dose Finding Study
    Interventions
    Cilastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-19
    Completion
    2018-08-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDose Finding Study
    InterventionCilastatin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy

    NCT02611271 · start 2017-12-01

    Registered record
    Registry ID
    NCT02611271
    Conditions
    Critical Illness; Sepsis; Acute Kidney Injury
    Interventions
    Monitoring of antibiotic drug removal
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-12-01
    Completion
    2020-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Sepsis; Acute Kidney Injury
    InterventionMonitoring of antibiotic drug removal
    PhaseNot recorded
    Registry statusUnknown

  • A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

    NCT03230916 · start 2017-11-06

    Registered record
    Registry ID
    NCT03230916
    Conditions
    Suspected or Documented Gram-negative Bacterial Infection
    Interventions
    IMI/REL FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-11-06
    Completion
    2020-08-11
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuspected or Documented Gram-negative Bacterial Infection
    InterventionIMI/REL FDC
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Colistin Based Antibiotic Therapy

    NCT04764058 · start 2017-09-01

    Registered record
    Registry ID
    NCT04764058
    Conditions
    Septicemia; Bacterial Infections
    Interventions
    Tienam 500; Infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2017-09-01
    Completion
    2021-09-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepticemia; Bacterial Infections
    InterventionTienam 500; Infusion
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

    NCT02971423 · start 2016-10

    Registered record
    Registry ID
    NCT02971423
    Conditions
    Acinetobacter Baumannii Infection
    Interventions
    ETX2514; Placebo; Sulbactam; Imipenem/Cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10
    Completion
    2017-06-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii Infection
    InterventionETX2514; Placebo; Sulbactam; Imipenem/Cilastatin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Innovative Tools in Development of Antibiotics

    NCT03177720 · start 2016-05-29

    Registered record
    Registry ID
    NCT03177720
    Conditions
    Pneumonia
    Interventions
    Ciprofloxacin; Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-29
    Completion
    2021-07-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionCiprofloxacin; Imipenem
    PhasePhase 1
    Registry statusCompleted